ArticleOncoimmunology2015
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 67 citations in OpenAlex.
- Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies.Nature communications · 2026Review
- Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.Journal for immunotherapy of cancer · 2026Article
- Revisiting the past in light of current knowledge on γδ T cells in leishmaniasis.Frontiers in immunology · 2026Review
- Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications.Frontiers in immunology · 2026Review
- γδ T cells as critical anti-tumor immune effectors.Nature cancer · 2024Review
- γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment.Journal of translational medicine · 2024Review
- Article
- Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.Nature communications · 2024Article
- Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives.Frontiers in immunology · 2024Review
- Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer.Signal transduction and targeted therapy · 2023Article
- Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.Cancer immunology, immunotherapy : CII · 2023Article
- Exhausted intratumoral Vδ2Nature immunology · 2023Article
- Review
- Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment.Molecular cancer · 2023Review
- Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.Hematology reports · 2023Review
- Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?Frontiers in immunology · 2023Review
- γδ T cells in immunotherapies for B-cell malignancies.Frontiers in immunology · 2023Review
- Review
- Review
- Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vγ9Vδ2 T cells have a natural inclination to recognize malignant B cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.